title: Possible interaction between opioidergic and cholinergic systems of CA1 in cholestasis-induced amnesia in mice.
abstract: Bile duct ligation (BDL) induces primary biliary cirrhosis characterized by cholestasis, impaired liver function and cognition including impairment of memory formation and anxiety-like behaviors. Endogenous opioid and acetylcholine levels are elevated in animal model of cholestasis. In addition, there is no data about the effects of interaction opioidergic and cholinergic systems of dorsal hippocampus (CA1) on amnesia-induced by cholestasis. Male mice weighing 25-35 g were used in this study. Cholestasis was induced by the ligation of the common bile duct. One-trial step-down and hole-board paradigms were used for the assessment of memory retrieval and anxiety-like behaviors respectively. All drugs injected intra-CA1. The data showed that cholestasis (24 days after BDL) decreased memory retrieval. Sole intra-CA1 injection of higher dose of mecamylamine (0.125, 0.25, 0.5 and 1 μg/mice) and scopolamine (0.125, 0.25, 0.5 1 and 2 μg/mice) but not all doses of naloxone (0.0125, 0.025 and 0.05 μg/mice) decreased memory retrieval in the sham operated BDL. The ineffective doses of naloxone (0.025 and 0.05 μg/mice), mecamylamine (0.5 μg/mice) and scopolamine (0.5 μg/mice) restored cholestasis-induced amnesia 24 days after BDL. Further, all cross co-administration ineffective doses of naloxone (0.0125 μg/mice), mecamylamine (0.125 μg/mice) and scopolamine (0.125 μg/mice) reversed cholestasis-induced amnesia. All doses of the drugs have no effect on exploratory behaviors. The data strongly revealed that synergistic effect between opioidergic and cholinergic systems of CA1 on the modulation of cholestasis-induced amnesia.
authors.affiliation: Department of Neuroscience, School of Advanced Medical Technologies, Tehran University of Medical Sciences, Tehran, Iran. zarinmr@amss.ac.ir
authors.forename: Mohammad Reza
authors.initials: MR
authors.lastname: Zarrindast
authors.forename: Saereh
authors.initials: S
authors.lastname: Hoseindoost
authors.forename: Mohammad
authors.initials: M
authors.lastname: Nasehi
mesh_terms: D000647:Amnesia / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D000818:Animals; D021461:Animals, Outbred Strains; D056547:CA1 Region, Hippocampal / Q000187:drug effects / Q000502:physiology*; D002779:Cholestasis / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination / Q000379:methods / Q000523:psychology; D005106:Exploratory Behavior / Q000187:drug effects / Q000502:physiology; D008297:Male; D008464:Mecamylamine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D011939:Mental Recall / Q000187:drug effects / Q000502:physiology*; D051379:Mice; D008845:Microinjections; D018727:Muscarinic Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D009270:Naloxone / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D009292:Narcotic Antagonists; D018733:Nicotinic Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D011957:Receptors, Opioid / Q000502:physiology; D012601:Scopolamine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D018727:Muscarinic Antagonists; D009292:Narcotic Antagonists; D018733:Nicotinic Antagonists; D011957:Receptors, Opioid; D009270:Naloxone; D008464:Mecamylamine; D012601:Scopolamine